drugset / Trial / NCT05706324
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
Phase 1
Unknown
60 enrolled
Wuhan BravoVax Co., Ltd.
National University Hospital, Singapore · collabShanghai BravoBio Co., Ltd. · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation, RCVi) at low, medium, and high doses in healthy adults (previously primed with authorized vaccines).
Timeline
- Start
- 2023-06
- Primary completion
- 2023-12
- Completion
- 2024-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) | Vaccine | 0.2 ml | Inhaled |